Literature DB >> 33800130

Comparative Proteome Research in a Zebrafish Model for Vanishing White Matter Disease.

Doeun Kim1, Yu-Ri Lee2, Tae-Ik Choi2, Se-Hee Kim3, Hoon-Chul Kang3, Cheol-Hee Kim2, Sangkyu Lee1.   

Abstract

Vanishing white matter (VWM) disease is a genetic leukodystrophy leading to severe neurological disease and early death. VWM is caused by bi-allelic mutations in any of the five genes encoding the subunits of the eukaryotic translation factor 2B (EIF2B). Previous studies have attempted to investigate the molecular mechanism of VWN by constructing models for each subunit of EIF2B that causes VWM disease. The underlying molecular mechanisms of the way in which mutations in EIF2B3 result in VWM are largely unknown. Based on our recent results, we generated an eif2b3 knockout (eif2b3-/-) zebrafish model and performed quantitative proteomic analysis between the wild-type (WT) and eif2b3-/- zebrafish, and identified 25 differentially expressed proteins. Four proteins were significantly upregulated, and 21 proteins were significantly downregulated in eif2b3-/- zebrafish compared to WT. Lon protease and the neutral amino acid transporter SLC1A4 were significantly increased in eif2b3-/- zebrafish, and crystallin proteins were significantly decreased. The differential expression of proteins was confirmed by the evaluation of mRNA levels in eif2b3-/- zebrafish, using whole-mount in situ hybridization analysis. This study identified proteins which candidates as key regulators of the progression of VWN disease, using quantitative proteomic analysis in the first EIF2B3 animal model of VWN disease.

Entities:  

Keywords:  EIF2B; SLC1A4; Vanishing White Matter disease; comparative proteomics

Mesh:

Substances:

Year:  2021        PMID: 33800130      PMCID: PMC7962458          DOI: 10.3390/ijms22052707

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  38 in total

1.  eIF2B Mutations Cause Mitochondrial Malfunction in Oligodendrocytes.

Authors:  Melisa Herrero; Shir Mandelboum; Orna Elroy-Stein
Journal:  Neuromolecular Med       Date:  2019-05-27       Impact factor: 3.843

2.  Vanishing white matter disease caused by EIF2B2 mutation with the presentation of an adrenoleukodystrophy phenotype.

Authors:  Ahmed Alsalem; Ranad Shaheen; Fowzan S Alkuraya
Journal:  Gene       Date:  2012-01-17       Impact factor: 3.688

3.  Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination.

Authors:  Nadirah Damseh; Alexandre Simonin; Chaim Jalas; Joseph A Picoraro; Avraham Shaag; Megan T Cho; Barak Yaacov; Julie Neidich; Motee Al-Ashhab; Jane Juusola; Sherri Bale; Aida Telegrafi; Kyle Retterer; John G Pappas; Ellen Moran; Joshua Cappell; Kwame Anyane Yeboa; Bassam Abu-Libdeh; Matthias A Hediger; Wendy K Chung; Orly Elpeleg; Simon Edvardson
Journal:  J Med Genet       Date:  2015-06-03       Impact factor: 6.318

Review 4.  Gamma crystallins of the human eye lens.

Authors:  Venkata Pulla Rao Vendra; Ismail Khan; Sushil Chandani; Anbukkarasi Muniyandi; Dorairajan Balasubramanian
Journal:  Biochim Biophys Acta       Date:  2015-06-25

5.  Proteomics-level analysis of myelin formation and regeneration in a mouse model for Vanishing White Matter disease.

Authors:  Irit Gat-Viks; Tamar Geiger; Mali Barbi; Gali Raini; Orna Elroy-Stein
Journal:  J Neurochem       Date:  2015-05-14       Impact factor: 5.372

6.  A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter.

Authors:  Michal Geva; Yuval Cabilly; Yaniv Assaf; Nina Mindroul; Liraz Marom; Gali Raini; Dalia Pinchasi; Orna Elroy-Stein
Journal:  Brain       Date:  2010-08       Impact factor: 13.501

Review 7.  Emerging role of Lon protease as a master regulator of mitochondrial functions.

Authors:  Marcello Pinti; Lara Gibellini; Milena Nasi; Sara De Biasi; Carlo Augusto Bortolotti; Anna Iannone; Andrea Cossarizza
Journal:  Biochim Biophys Acta       Date:  2016-03-28

8.  Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.

Authors:  Mika Terumitsu-Tsujita; Hiroki Kitaura; Ikuo Miura; Yuji Kiyama; Fumiko Goto; Yoshiko Muraki; Shiho Ominato; Norikazu Hara; Anna Simankova; Norihisa Bizen; Kazuhiro Kashiwagi; Takuhiro Ito; Yasuko Toyoshima; Akiyoshi Kakita; Toshiya Manabe; Shigeharu Wakana; Hirohide Takebayashi; Hironaka Igarashi
Journal:  J Neurochem       Date:  2019-10-28       Impact factor: 5.372

9.  Mutations in FAM50A suggest that Armfield XLID syndrome is a spliceosomopathy.

Authors:  Yu-Ri Lee; Kamal Khan; Kim Armfield-Uhas; Sujata Srikanth; Nicola A Thompson; Mercedes Pardo; Lu Yu; Joy W Norris; Yunhui Peng; Karen W Gripp; Kirk A Aleck; Chumei Li; Ed Spence; Tae-Ik Choi; Soo Jeong Kwon; Hee-Moon Park; Daseuli Yu; Won Do Heo; Marie R Mooney; Shahid M Baig; Ingrid M Wentzensen; Aida Telegrafi; Kirsty McWalter; Trevor Moreland; Chelsea Roadhouse; Keri Ramsey; Michael J Lyons; Cindy Skinner; Emil Alexov; Nicholas Katsanis; Roger E Stevenson; Jyoti S Choudhary; David J Adams; Cheol-Hee Kim; Erica E Davis; Charles E Schwartz
Journal:  Nat Commun       Date:  2020-07-23       Impact factor: 14.919

10.  A Novel SLC1A4 Mutation (p.Y191*) Causes Spastic Tetraplegia, Thin Corpus Callosum, and Progressive Microcephaly (SPATCCM) With Seizure Disorder.

Authors:  Hanadi A Abdelrahman; Aisha Al-Shamsi; Anne John; Bassam R Ali; Lihadh Al-Gazali
Journal:  Child Neurol Open       Date:  2019-10-08
View more
  2 in total

Review 1.  Human iPSC-Derived Astrocytes: A Powerful Tool to Study Primary Astrocyte Dysfunction in the Pathogenesis of Rare Leukodystrophies.

Authors:  Angela Lanciotti; Maria Stefania Brignone; Pompeo Macioce; Sergio Visentin; Elena Ambrosini
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

Review 2.  Emerging cellular themes in leukodystrophies.

Authors:  Joseph C Nowacki; Ashley M Fields; Meng Meng Fu
Journal:  Front Cell Dev Biol       Date:  2022-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.